Shareholder letter - Monday May 13, 2013Link to document. RegeneRx PipelineRegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.
* In March 2011 the FDA placed a “clinical hold” on our Phase 2 AMI trial due to cGMP issues at a contract manufacturer’s site formulating RGN-352. The timing for the resumption of this trial is unclear. The reader is referred to our press releases dated March 16 and April 14, 2011. |
May 13, 2013
RegeneRx Issues Letter to Shareholders
April 1, 2013
RegeneRx Issues $225,000 Convertible Note
March 8, 2013
RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent
February 7, 2013
RegeneRx Receives Notice of Allowance from Chinese Patent Office for Treatment and Prevention of Heart Disease
November 5, 2012
RegeneRx Receives Notice of Allowance from U.S. Patent Office for New Ophthalmic Indications
October 22, 2012
RegeneRx Issues $300,000 Convertible Note To Pursue Current Initiatives